IP Library Granted Patent US 12,705,311
Granted Patent B2
US 12,705,311 · App. 18/882,211 · Granted Aug 11, 2026

Communication generation using sparse indicators and sensor data

Inventors: Ryan Barrett (San Francisco, CA); Nishant Bhat (San Francisco, CA); Huy Hong (Palo Alto, CA); Katsuya Noguchi (San Francisco, CA); Wendy McKennon (San Francisco, CA); Krishna Pant (San Jose, CA); Taylor Sittler (San Francisco, CA); Othman Laraki (Atherton, CA); Elad Gil (San Francisco, CA)
Assignee: Color Health, Inc.
G06F18/285G06F18/23G06Q10/00G16B20/20G16B25/00G16H10/60H10W20/064G06F2218/00G06Q10/063G16B20/10G16B25/10G16B30/00G16B30/10G16B50/00G16H40/67H10W20/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,705,311
App. No.
18/882,211
Filed
Sep 11, 2024
Granted
Aug 11, 2026
Kind
B2
Art Unit
2447
USPC
707/756
Abstract

Genetic-variant data is obtained that corresponds to one or more variants associated with a client. Each of the one or more variants corresponds to an instance of one or more bases positioned at one or more first positions in a first genetic sequence differ from corresponding one or more bases positioned in a reference genetic sequence. The first genetic sequence is a genetic sequence of the client. Sensor data is obtained that provides an indication of one or more characteristics of a current or past environment of the client. The genetic-variant data and the sensor data is processed to generate a disease-risk metric corresponding to a predicted risk of the client developing a particular disease. A communication is generated that is indicative of the disease-risk metric. The communication is transmitted to a remote device.

Claims (42)

1 . A computer-implemented method comprising:

accessing genetic-variant data corresponding to one or more variants associated with a client, wherein each of the one or more variants corresponds to an instance of one or more bases positioned at one or more first positions in a first genetic sequence differ from corresponding one or more bases positioned in a reference genetic sequence, wherein the first genetic sequence is a genetic sequence of the client;

predicting a reliability of the genetic-variant data by transforming an input data set using an artificial intelligence technique, wherein the input data set indicates a laboratory, device, or a collection time period associated with the genetic-variant data;

obtaining other data that include at least sensor data;

processing, based on the reliability of the genetic-variant data, the genetic-variant data and the other data to generate a disease-risk metric corresponding to a predicted risk of the client developing a particular disease;

generating a communication indicative of the disease-risk metric; and

availing the communication to a remote device.

2 . The computer-implemented method of claim 1 , wherein the input data set indicates a laboratory, and wherein the artificial intelligence technique is used to predict the reliability based on the laboratory.

3 . The computer-implemented method of claim 1 , wherein the input data set indicates an equipment device, and wherein the artificial intelligence technique is used to predict the reliability based on the equipment device.

4 . The computer-implemented method of claim 1 , wherein the input data set indicates a time or time period, and wherein the artificial intelligence technique is used to predict the reliability based on the time or time period.

5 . The computer-implemented method of claim 1 , further comprising:

identifying a normalization and/or conversion factor for the genetic-variant data using a clustering technique wherein the processing performed to generate the disease-risk metric is further based on the normalization and/or conversion factor.

6 . The computer-implemented method of claim 1 , wherein the reliability is predicted using the collection time period and by performing a time-series analysis associated with a data-collection component associated with the genetic-variant data.

7 . The computer-implemented method of claim 1 , wherein the artificial intelligence technique uses a transformation and/or dimensionality reduction technique that includes principal component analysis, independent component analysis, or canonical correspondence analysis.

8 . The computer-implemented method as recited in claim 1 , wherein the sensor data includes data from an accelerometer and provides an indication of past physical activity of the client.

9 . A system for generating communications based on variant information and sensor data, comprising:

one or more hardware processors; and

a non-transitory computer readable storage medium in data communication with the one or more hardware processors, the non-transitory computer readable storage medium comprising instructions that, when executed by the one or more hardware processors, cause the one or more hardware processors to perform operations including:

obtain, at the one or more hardware processors, genetic-variant data corresponding to one or more variants associated with a client, wherein each of the one or more variants corresponds to an instance of one or more bases positioned at one or more first positions in a first genetic sequence differ from corresponding one or more bases positioned in a reference genetic sequence, wherein the first genetic sequence is a genetic sequence of the client;

predict a reliability of the genetic-variant data by performing a comparison of the genetic-variant data based on different labs, different devices, or different time periods associated with data collection;

obtain other data that include at least sensor data providing an indication of one or more characteristics of the client, current quality of the client, behavior of the client, or one or more characteristics of a current or past environment of the client;

process, based on the reliability of the genetic-variant data, the genetic-variant data and the other data to generate a disease-risk metric corresponding to a predicted risk of the client developing a particular disease;

generate a communication indicative of the disease-risk metric; and

availing the communication to a remote device.

10 . The system of claim 9 , wherein the input data set indicates a laboratory, and wherein the artificial intelligence technique is used to predict the reliability based on the laboratory.

11 . The system of claim 9 , wherein the input data set indicates an equipment device, and wherein the artificial intelligence technique is used to predict the reliability based on the equipment device.

12 . The system of claim 9 , wherein the input data set indicates a time or time period, and wherein the artificial intelligence technique is used to predict the reliability based on the time or time period.

13 . A computer-program product tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to cause one or more data processors to perform a set of operations including:

accessing genetic-variant data corresponding to one or more variants associated with a client, wherein each of the one or more variants corresponds to an instance of one or more bases positioned at one or more first positions in a first genetic sequence differ from corresponding one or more bases positioned in a reference genetic sequence, wherein the first genetic sequence is a genetic sequence of the client;

predicting a reliability of the genetic-variant data by transforming an input data set using an artificial intelligence technique, wherein the input data set indicates a laboratory, device, or a collection time period associated with the genetic-variant data;

obtaining other data that include at least sensor data;

processing, based on the reliability of the genetic-variant data, the genetic-variant data and the other data to generate a disease-risk metric corresponding to a predicted risk of the client developing a particular disease;

generating a communication indicative of the disease-risk metric; and

availing the communication to a remote device.

14 . The computer-program product of claim 13 , wherein the input data set indicates a laboratory, and wherein the artificial intelligence technique is used to predict the reliability based on the laboratory.

15 . The computer-program product of claim 13 , wherein the input data set indicates an equipment device, and wherein the artificial intelligence technique is used to predict the reliability based on the equipment device.

16 . The computer-program product of claim 13 , wherein the input data set indicates a time or time period, and wherein the artificial intelligence technique is used to predict the reliability based on the time or time period.

17 . The computer-program product of claim 13 , wherein the set of operations further includes:

identifying a normalization and/or conversion factor for the genetic-variant data using a clustering technique wherein the processing performed to generate the disease-risk metric is further based on the normalization and/or conversion factor.

18 . The computer-program product of claim 13 , wherein the reliability is predicted using the collection time period and by performing a time-series analysis associated with a data-collection component associated with the genetic-variant data.

19 . The computer-program product of claim 13 , wherein the artificial intelligence technique uses a transformation and/or dimensionality reduction technique that includes principal component analysis, independent component analysis, or canonical correspondence analysis.

20 . The computer-program product as recited in claim 13 , wherein the sensor data includes data from an accelerometer and provides an indication of past physical activity of the client.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2024
From: BARRETT, RYAN; BHAT, NISHANT; HONG, HUY; NOGUCHI, KATSUYA; MCKENNON, WENDY; PANT, KRISHNA; SITTLER, TAYLOR; LARAKI, OTHMAN; GIL, ELAD
To: COLOR GENOMICS, INC.
Reel/Frame 068806/0292 →
CHANGE OF NAME Recorded Oct 4, 2024
From: COLOR GENOMICS, INC.
To: COLOR HEALTH, INC.
Reel/Frame 069134/0300 →
Continuity (17)
Continuation 18474868 · Sep 26, 2023
Continuation 17742337 · May 11, 2022
Continuation 17394181 · Aug 4, 2021
Continuation 16919351 · Jul 2, 2020
Continuation 15683495 · Aug 22, 2017
Continuation In Part 15489473 · Apr 17, 2017
Continuation In Part 15406394 · Jan 13, 2017
Continuation In Part 15169294 · May 31, 2016
Continuation In Part 15163191 · May 24, 2016
Continuation In Part 15133089 · Apr 19, 2016
Provisional Application 62324080 · Apr 18, 2016
Provisional Application 62304487 · Mar 7, 2016
Provisional Application 62303531 · Mar 4, 2016
Provisional Application 62274660 · Jan 4, 2016
Provisional Application 62261982 · Dec 2, 2015
Provisional Application 62150218 · Apr 20, 2015
Related Publication 20250005110A1 · Jan 2, 2025
References Cited (69)
US 6542896B1 · Gruenwald · 2003 [cited by applicant]
US 6691109B2 · Bjornson et al. · 2004 [cited by applicant]
US 7801591B1 · Shusterman · 2010 [cited by applicant]
US 9354922B2 · Lee · 2016 [cited by applicant]
US 9584882B1 · Barrett et al. · 2017 [cited by applicant]
US 9679104B2 · van Rooyen · 2017 [cited by examiner]
US 9773031B1 · Pant et al. · 2017 [cited by applicant]
US 9774508B1 · Barrett et al. · 2017 [cited by applicant]
US 9785792B2 · Barrett et al. · 2017 [cited by applicant]
US 9811552B1 · Noguchi et al. · 2017 [cited by applicant]
US 10733476B1 · Barrett et al. · 2020 [cited by applicant]
US 20020187496A1 · Andersson et al. · 2002 [cited by applicant]
US 20030040002A1 · Ledley · 2003 [cited by applicant]
US 20040133358A1 · Bryant et al. · 2004 [cited by applicant]
US 20050001520A1 · Cummings · 2005 [cited by applicant]
US 20060010117A1 · Bonabeau et al. · 2006 [cited by applicant]
US 20070288439A1 · Rappaport et al. · 2007 [cited by applicant]
US 20090094059A1 · Coleman et al. · 2009 [cited by applicant]
US 20100115421A1 · Bejjani et al. · 2010 [cited by applicant]
US 20100121872A1 · Subramaniam · 2010 [cited by applicant]
US 20100153017A1 · De La Vega et al. · 2010 [cited by applicant]
US 20110004110A1 · Shusterman · 2011 [cited by applicant]
US 20110098193A1 · Kingsmore et al. · 2011 [cited by applicant]
US 20120046877A1 · Hyland et al. · 2012 [cited by applicant]
US 20120196571A1 · Grkov et al. · 2012 [cited by applicant]
US 20140032125A1 · Hawkins · 2014 [cited by applicant]
US 20140108074A1 · Miller et al. · 2014 [cited by applicant]
US 20140304270A1 · Torkamani · 2014 [cited by examiner]
US 20140325587A1 · Nilsson et al. · 2014 [cited by applicant]
US 20140331084A1 · Sawazaki et al. · 2014 [cited by applicant]
US 20150006548A1 · Huang et al. · 2015 [cited by applicant]
US 20150056613A1 · Kural · 2015 [cited by applicant]
US 20150088786A1 · Anandhakrishnan et al. · 2015 [cited by applicant]
US 20150213389A1 · Modarresi · 2015 [cited by applicant]
US 20150275289A1 · Otwinowski et al. · 2015 [cited by applicant]
US 20150310182A1 · Henze et al. · 2015 [cited by applicant]
US 20150322507A1 · Zimmermann · 2015 [cited by examiner]
US 20150370840A1 · Wilhelm et al. · 2015 [cited by applicant]
US 20150379193A1 · Bassett, Jr. et al. · 2015 [cited by applicant]
US 20160048564A1 · Bassett, Jr. et al. · 2016 [cited by applicant]
US 20160049071A1 · Beaver et al. · 2016 [cited by applicant]
US 20160066189A1 · Mahaffey et al. · 2016 [cited by applicant]
US 20160239604A1 · Chudova et al. · 2016 [cited by applicant]
US 20160253452A1 · Karbassi et al. · 2016 [cited by applicant]
US 20160275239A1 · Devogelaere et al. · 2016 [cited by applicant]
WO WO02080079A2 · 2002 [cited by examiner]
WO 2012006291A2 · 2012 [cited by applicant]
WO 2015061359A1 · 2015 [cited by applicant]
Baskin et al., “Implementiing ACMG Guidelines on Sequence Variant Interpretation: Software-Assisted Variant Curation and Filtering”, Cartagenia Bench Lab, published Oct. 2016. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/163,191 dated Dec. 7, 2016. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/683,495, dated Jan. 2, 2020. [cited by applicant]
First Action Interview Office Action Summary for U.S. Appl. No. 15/683,495, dated Sep. 10, 2019. [cited by applicant]
First Action Interview Pilot Program Pre-Interview Communication for U.S. Appl. No. 15/133,089 mailed Feb. 27, 2017. [cited by applicant]
First Action Interview Pilot Program Pre-Interview Communication for U.S. Appl. No. 15/169,294 dated Aug. 23, 2016. [cited by applicant]
First Action Interview Pilot Program Pre-Interview Communication for U.S. Appl. No. 16/683,495, dated Jun. 17, 2019. [cited by applicant]
Kassahn et al., “Integrating Massively Parallel Sequencing into Diagnostic Workflow and Managing the Annotation and Clinical Interpretation Challenge”, Office Journal Human Genome Variation Society, published Feb. 2014. [cited by applicant]
Loria, “A New $100 Million Company Could Transform the Way we Interact with our own DNA”, “Business Insider”, Aug. 24, 2015, all pages. Retrieved from: http://www.businessinsider.com/what-helix-could-learn-from-genome-s… [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/742,337, dated Jan. 19, 2023. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/133,089 dated Jun. 19, 2017. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/169,294, dated Nov. 4, 2016. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/406,394, dated Aug. 25, 2017. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/406,394 dated May 25, 2017. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/489,473 dated Jul. 18, 2017. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/683,495, dated Mar. 26, 2020. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/919,351, dated May 27, 2021. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/394,181, dated Feb. 16, 2022. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/742,337, dated Jun. 12, 2023. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/474,868, dated May 28, 2024. [cited by applicant]
Richards et al., “Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association of Molecular Patholog… [cited by applicant]